A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 81-85

  Krivak, Thomas C ^a   Tian, Chunqiao ^b   Rose, G Scott ^c   Armstrong, Deborah K ^d   Maxwell, G Larry ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CA 125; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; PACLITAXEL;

ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 69249217753     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.021     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer Statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Rustin G.J., Gennings J.N., Nelstrop A.E., Covarrubias H., Lambert H.E., and Bagshawe K.D. Use of CA-1225 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J. Clin. Oncol. 7 (1989) 1667-1671
3. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J. Clin. Oncol. 14 (1996) 1545-1551
4. Markman M., Federico M., Liu P.Y., Hannigan E., and Alberts D. Significance of early changes in the serum Ca-125 antigen level on overall survival in advanced ovarian cancer. Gynecol. Oncol. 103 (2006) 195-198
5. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
6. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
7. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
8. Makhija S., Spanos W.J., Day Jr. T.G., and Doering D. CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients. Gynecol. Oncol. 63 (1996) 85-88
9. Richardson D.L., Seamon L.G., Carlson M.J., O'Malley D.M., Fowler J.M., Copeland L.J., et al. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal chemotherapy. Gynecol. Oncol. 111 (2008) 233-236
10. Collett D. Modeling survival data in medical research (2nd ed) (2003), Chapman & Hall/CRC
11. Bast Jr. R.C., Freeney M., Lazarus H., et al. Reactivity of a monocloncal antibody with human ovarian carcinoma. J. Clin. Invest. 68 (1981) 1331-1337
12. Bast Jr. R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309 (1983) 883-887
13. Jacobs I., and Bast Jr. R.C. The Ca-125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4 (1989) 1-12
14. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol. Oncol. 77 (2000) 227-231
15. Zorn KK, Armstrong DK, Tian C, McGuire WP, Hoskins WJ, Markman M, et al. Significance of pre-treatment CA-125 level in advanced ovarian carcinoma: a meta-analysis of seven gynecologic oncology group protocols. Abstract, 2007, Society of Gynecologic Oncologists.
16. Crawford S.M., and Peace J. Does the nadir Ca-125 concentration predict long-term outcome after chemotherapy for carcinoma of the ovary?. Ann. Oncol. 16 (2005) 47-50
17. Markman M., Liu P.Y., Rothenberg M.L., Monk B.J., Brady M., and Alberts D.S. Pretreatment CA-125 and the risk of relapse in advanced ovarian cancer. J. Clin. Oncol. 24 (2006) 1454-1458
18. Juretzka M.M., Barakat R.R., Chi D.S., Iasonos A., Dupont J., Abu-Rustum N.R., et al. CA125 level as a predictor of progression free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol. Oncol. 104 (2007) 176-180
19. Zeimet A.G., Marth C., Offner F.A., et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol. Oncol. 62 (1996) 384-389
20. Epiney M., Bertossa C., Weil A., Campana A., and Bischof P. CA125 production by the peritoneum: in-vitro and in-vivo studies. Human. Reprod. 15 (2000) 1261-1265
21. Van der Zee A.G., Duk J., Aalders J.G., et al. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA125. Br. J. Obstet. Gynaecol. 97 (1990) 934-938
22. Yedema C.A., Kenemans P., Thomas C.M., et al. CA 125 serum levels in the early postoperative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur. J. Cancer 29 (1993) 966-971
23. Bergmann J.F., Bidart J.M., George M., Beaugrand M., Levy V.G., and Bohuon C. Elevation of CA-125 in patients with benign and malignant ascites. Cancer 59 (1987) 213-217
24. Sevinc A., Buyukberber S., Sari R., Kiroqlu Y., Turk H.M., and Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol. Oncol. 77 (2000) 254-257
25. Buller R.E., Berman M.L., Bloss J.D., Manetta A., and DiSaia P.J. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol. Oncol. 47 (1992) 87-92
26. Richard S.D., Lesnock J.L., Sukumvanich P., Zorn K.K., Edwards R.P., Kelley J.L., et al. Intraperitoneal catheter may prolong time to normalization of CA125 levels. Abstract 95 (March 2008), SGO, Tampa FL